(Reuters) – Regeneron Pharmaceuticals said on Thursday it would make an upfront payment of $900 million to buy the global rights to cancer drug Libtayo from Sanofi SA.
Regeneron and Sanofi had in 2015 entered into a collaboration agreement under which they split the drug’s worldwide profits equally.
(Reporting by Amruta Khandekar)
